How much are Amicus Therapeutics’ shares worth?

How much are Amicus Therapeutics’ shares worth?

Amicus Therapeutics (NASDAQ: FOLD) reported this week positive data from study 012 of its chaperone small molecule migalastat (Amigal) in patients with Fabry disease. Fabry is a rare disease that affects about 1 person in 117,000 people or about 5,000 patients evenly distributed between Europe and the United States. The hallmark of the disease is the accumulation of the substrate globotriaosylceramide (Gb3) in the kidneys. For more information on Fabry, visit this link. [Read more...]

Biotech markets news. June 2014

- Morphosys (MOR.DE) and Merck Serono (MRK.DE) enter into immuno-oncology agreement. (cont’d)
- AstraZeneca (AZN) and Synairgen strike asthma deal.
- Kite Pharma (KITE) sets price range ahead of IPO.
- Orexigen Therapeutics (OREX) gets a 3 month delay for Contrave’s PDUFA.
- GSK and Theravance (THRX)  report positive Phase III data of ICS/LAMA/LABA combo in COPD.

[Read more...]

Biomarkets on the move. March 2014.

Biomarkets on the move. March 2014.

- Circassia raises $332M in London IPO (CIR.L)
- Vectura (VEC.L) acquiring Activaero, raises GBP200M in placing.
- Venrock plans $200M fund.
- Tesaro (TSRO) and AnaptysBio team up on cancer immunotherapies for $125M
- Charles River to acquire Galapagos (GLPG.BR) service divisions

[Read more...]